Related Experiment Video

Updated: Apr 5, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K

A Small Molecule Inhibits Deregulated NRF2 Transcriptional Activity in Cancer

Michael J Bollong1, Hwayoung Yun1, Lance Sherwood2

  • 1Department of Chemistry, The Scripps Research Institute , 10550, North Torrey Pines, La Jolla, California 92037, United States.

ACS Chemical Biology
|August 14, 2015
PubMed

Insights

A novel small molecule, AEM1, inhibits the master regulator of oxidative stress, NRF2 (Nuclear factor erythroid 2-related factor 2). This compound shows promise for treating cancers driven by NRF2 mutations, enhancing chemotherapy efficacy and reducing tumor growth.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Nuclear factor erythroid 2-related factor 2 (NRF2) is crucial for cellular oxidative stress resistance.
  • Cancer cells often exploit NRF2 mutations for growth and chemoresistance.
  • Targeting NRF2 offers a potential therapeutic strategy for NRF2-dependent cancers.

Discussion:

  • A high-throughput screen identified AEM1, a small molecule inhibiting NRF2 transcriptional activity.
  • AEM1 decreases NRF2-controlled gene expression, sensitizes cancer cells to chemotherapy, and inhibits tumor growth in vitro and in vivo.
  • AEM1's efficacy is specific to cancer cell lines with constitutively active NRF2 mutations.

Key Insights:

  • AEM1 effectively suppresses NRF2-driven cancer cell proliferation and chemoresistance.
  • The compound demonstrates targeted activity against cancers with specific NRF2 mutations.
  • AEM1 represents a promising therapeutic lead for NRF2-dependent malignancies.

Outlook:

  • Further investigation into AEM1's mechanism of action and therapeutic potential is warranted.
  • Development of AEM1 could lead to new treatments for specific cancer types.
  • This research opens avenues for targeted therapies exploiting cancer-specific NRF2 dependencies.

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.0K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.4K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K